3SBIO plans to allocate 31.1425 million shares to Pfizer, netting approximately HKD 785 million
I'm PortAI, I can summarize articles.
3SBIO announced that it has signed a licensing agreement with Pfizer, involving the PD-1/VEGF bispecific antibody (SSGJ-707). The agreement will take effect on July 24, 2025. Pfizer agrees to subscribe for 31.1425 million shares at a price of HKD 25.2055 per share, raising approximately HKD 785 million, with the subscription price representing a discount of about 17.09% to the market closing price
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments